Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Dolutegravir Expanded Access Study (DEAP)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2011 by ViiV Healthcare.
Recruitment status was  Available
Information provided by:
ViiV Healthcare Identifier:
First received: February 16, 2012
Last updated: February 21, 2012
Last verified: December 2011
ING114916 is an open-label, multi-center, expanded access (EAP) study

Condition Intervention
Infection, Human Immunodeficiency Virus
Drug: dolutegravir

Study Type: Expanded Access     What is Expanded Access?
Official Title: A GSK1349572 Open Label Protocol for HIV Infected, Adult Patients With Integrase Resistance

Resource links provided by NLM:

Further study details as provided by ViiV Healthcare:

Study Start Date: February 2012
Intervention Details:
    Drug: dolutegravir
    integrase inhibitor in development
Detailed Description:

ING114916 is an open-label, multi-center EAP to allow access to patients with HIV-1 infection who have documented raltegravir or elvitegravir resistance, have limited treatment options and require dolutegravir to construct a viable anti-retroviral regimen for therapy. Patients must not be eligible for another ongoing dolutegravir clinical trial in order to participate in this EAP.

The duration of patient accrual into the study will extend until dolutegravir receives local (by country) regulatory approval.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:Adult subjects greater than 18 years of age, documented HIV-1 RNA >/= 400 c/mL, documented raltegravir or elvitegravir resistance, inability to construct a viable background ART regimen with commercially available medications.

Exclusion Criteria: Creatnine clearance < 30ml/min via Cockcroft-Gault method, females who are pregnant and/or breastfeeding, patients with known integrase allergic reaction, ALT > 5 times the ULN within one month of treatment initiation, ALT > 3 times ULN and total bilirubin >1.5 times ULN, evidence of severe hepatic impairment, patients eligible for, and have access to, an actively enrolling DTG Phase III clinical study, any condition or any active clinically significant disease during screening, anticipated requirement for any prohibited concomitant medications

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01536873

Contact: US GSK Clinical Trials Call Center 877-379-3718

Sponsors and Collaborators
ViiV Healthcare
Study Director: GSK Clinical Trials ViiV Healthcare
  More Information

Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure Identifier: NCT01536873     History of Changes
Other Study ID Numbers: 114916 
Study First Received: February 16, 2012
Last Updated: February 21, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by ViiV Healthcare:
treatment experienced patients
Integrase resistance

Additional relevant MeSH terms:
Immunologic Deficiency Syndromes
Acquired Immunodeficiency Syndrome
HIV Infections
Immune System Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
HIV Integrase Inhibitors
Integrase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents processed this record on October 21, 2016